Pamidronic acid

Generic Name: Pamidronic acid

Brand Names: Pamisol

Drug Type: Small Molecule

Chemical Formula: C_₃H_₁₁NO_₇P_₂

CAS Number: 40391-99-9

Unique Ingredient Identifier: OYY3447OMC

Background: Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming more popular.

Pamidronic acid was granted FDA approval on 31 October 1991.

Indication: Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.

Associated Conditions: Hypercalcemia of Malignancy, Osteolytic lesion, Paget’s Disease, Osteolytic Bone metastases

Clinical Trials

Exploring Non-Opioid Options for Chronic Pain Management

11 years ago

• A review of studies highlights several non-opioid medications with potential benefits for chronic low back pain (CLBP), myofascial pain syndrome (MPS), and fibromyalgia (FM). • For CLBP, NSAIDs, antidepressants (duloxetine), and muscle relaxants (carisoprodol, cyclobenzaprine, diazepam) have demonstrated efficacy compared to placebo in some studies. • Pregabalin and duloxetine have shown superior pain relief compared to placebo for fibromyalgia, while lidocaine patches and BoNT-A injections may benefit myofascial pain syndrome. • Several studies suggest that combination therapies, such as nortriptyline/gabapentin and morphine/gabapentin, may offer enhanced pain relief and reduced side effects compared to monotherapy.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy